10 Best Mid Cap Pharma Stocks to Buy

Page 9 of 9

1. Revolution Medicines Inc. (NASDAQ:RVMD)

Market Capitalization as of July 22: $7.13 billion

Number of Hedge Fund Holders: 61

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best mid cap pharma stocks to buy. On July 9, Revolution Medicines Iambic Therapeutics, which is a clinical-stage life science and technology company, announced a multi-year technology and research collaboration. The partnership aims to discover novel drug candidates for RAS-addicted cancers by using Iambic’s leading AI models.

Under the agreement, Iambic will use structures and molecular libraries provided by Revolution Medicines to train customized versions of NeuralPLexer, which is Iambic’s protein-ligand structure prediction model. Revolution Medicines will also gain access to Iambic’s PropANE model, which is a pre-trained graph neural network used for lead selection and optimization across numerous drug properties.

Iambic will develop custom versions of NeuralPLexer and other technologies, trained on Revolution Medicines’ proprietary data, to inform drug discovery against novel targets. Both companies will have access to these improved models. Each company will also retain rights to a limited number of exclusive targets and the ability to designate additional exclusive targets for independent pursuit.

Revolution Medicines Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers.

While we acknowledge the potential of RVMD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RVMD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9